Skip to main content

Group B Streptococcal Infections

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
2
Group B streptoccous 6-valent polysaccharide conjugate vaccinePhase 2Vaccine1 trial
Multivalent group B streptococcus vaccinePhase 2Vaccine1 trial
Active Trials
NCT04258995Completed151Est. Sep 2020
NCT03170609Completed365Est. Jun 2018
MinervaX
MinervaXDenmark - Copenhagen
1 program
1
GBS-NN/NN2Phase 1
IQVIA
IQVIADURHAM, NC
1 program
GBS-NN/NN2PHASE_11 trial
Active Trials
NCT05782179Completed90Est. May 2024
Inventprise
InventpriseWA - Redmond
1 program
IVT GBS-06PHASE_1_21 trial
Active Trials
NCT06611371Active Not Recruiting600Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerGroup B streptoccous 6-valent polysaccharide conjugate vaccine
PfizerMultivalent group B streptococcus vaccine
InventpriseIVT GBS-06
IQVIAGBS-NN/NN2

Clinical Trials (4)

Total enrollment: 1,206 patients across 4 trials

NCT04258995PfizerGroup B streptoccous 6-valent polysaccharide conjugate vaccine

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

Start: Feb 2020Est. completion: Sep 2020151 patients
Phase 2Completed
NCT03170609PfizerMultivalent group B streptococcus vaccine

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Start: Jun 2017Est. completion: Jun 2018365 patients
Phase 2Completed
NCT06611371InventpriseIVT GBS-06

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

Start: Nov 2024Est. completion: Feb 2026600 patients
Phase 1/2Active Not Recruiting
NCT05782179IQVIAGBS-NN/NN2

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Start: Mar 2023Est. completion: May 202490 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.